跳至主要内容
临床试验/DRKS00009749
DRKS00009749招募中不适用

Early effects of TNF-alpha blocking on pain scores and quantitative sensory testing in patients with active rheumatoid arthritis

Funktionsbereich Rheumatologie | Klinik für Innere Medizin III | Universitätsklinikum Jena0 个研究点目标入组 60 人开始时间: 2016年1月18日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • (1) diagnosis rheumatoid arthritis (2010 ACR criteria)
  • (2) active rheumatoid arthritis (DAS>=2.6)
  • (3) physicians decision (in accordance with EULAR guidelines) to initiate methotrexate treatment or to change treatment from synthetic disease modifying drug (sDMARD) to TNF-alpha-blocking biologic DMARD (Infliximab, Etanercept, Adalimumab, Certolizumab or Golimumab)
  • (4) written informed consent

排除标准

  • (1) non-rheumatoid arthritis associated neuropathies and/or polyneuropathies (including diabetic neuropathy)
  • (2) severe neurological disease (e.g. apoplex, morbus parkinson)
  • (3) acute psychiatric disease requiring treatment (e.g. depression, schizophrenia)

研究者

发起方
Funktionsbereich Rheumatologie | Klinik für Innere Medizin III | Universitätsklinikum Jena

相似试验